Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 75

1.

The incidence and prognosis of renal dysfunction following cardioversion of atrial fibrillation.

Hellman Y, Cohen MJ, Leibowitz D, Loncar S, Gozal D, Haviv YS, Haber G, Afifi M, Rosenheck S, Lotan C, Pollak A, Gilon D.

Cardiology. 2013;124(3):184-9. doi: 10.1159/000346618. Epub 2013 Mar 9.

PMID:
23485988
2.

Renal dysfunction and atrial fibrillation recurrence following cardioversion.

Schmidt M, Daccarett M, Rittger H, Marschang H, Holzmann S, Jung P, Bojanic D, Ketteler M, Brachmann J, Rieber J.

J Cardiovasc Electrophysiol. 2011 Oct;22(10):1092-8. doi: 10.1111/j.1540-8167.2011.02069.x. Epub 2011 Apr 13.

PMID:
21489032
3.

Relapse and mortality following cardioversion of new-onset vs. recurrent atrial fibrillation and atrial flutter in the elderly.

Elesber AA, Rosales AG, Herges RM, Shen WK, Moon BS, Malouf JF, Ammash NM, Somers V, Hodge DO, Gersh BJ, Hammill SC, Friedman PA.

Eur Heart J. 2006 Apr;27(7):854-60. Epub 2006 Feb 2.

PMID:
16455671
4.

The effects of direct current cardioversion for persistent atrial fibrillation on indices of endothelial damage/dysfunction.

Freestone B, Chong AY, Blann AD, Lip GY.

Thromb Res. 2006;118(4):479-85. Epub 2005 Nov 28.

PMID:
16318868
6.
7.

Thirty-day outcomes of emergency department patients undergoing electrical cardioversion for atrial fibrillation or flutter.

Xavier Scheuermeyer F, Grafstein E, Stenstrom R, Innes G, Poureslami I, Sighary M.

Acad Emerg Med. 2010 Apr;17(4):408-15. doi: 10.1111/j.1553-2712.2010.00697.x.

8.

Functional capacity before and after cardioversion of atrial fibrillation: a controlled study.

Gosselink AT, Crijns HJ, van den Berg MP, van den Broek SA, Hillege H, Landsman ML, Lie KI.

Br Heart J. 1994 Aug;72(2):161-6.

9.

The effect of patient sex on recurrence of atrial fibrillation following successful direct current cardioversion.

Gurevitz OT, Varadachari CJ, Ammash NM, Malouf JF, Rosales AG, Herges RM, Bruce CJ, Somers VK, Hammill SC, Gersh BJ, Friedman PA.

Am Heart J. 2006 Jul;152(1):155.e9-13.

PMID:
16824847
10.

[Late recurrences of atrial fibrillation in patients after direct-current cardioversion].

Gurciková M, Kaluzay J, Remisová S, Jurkovicová O, Pontuch P.

Vnitr Lek. 2008 Jun;54(6):604-8. Slovak.

PMID:
18672570
11.

Role of prophylactic anticoagulation for direct current cardioversion in patients with atrial fibrillation or atrial flutter.

Arnold AZ, Mick MJ, Mazurek RP, Loop FD, Trohman RG.

J Am Coll Cardiol. 1992 Mar 15;19(4):851-5.

12.

[Predictive factors of maintenance of sinus rhythm after direct current (DC) cardioversion of atrial fibrillation/atrial flutter].

Larsen MT, Lyngborg K, Pedersen F, Corell P.

Ugeskr Laeger. 2005 Sep 5;167(36):3408-12. Danish.

PMID:
16159494
13.

Long-term prognosis after cardioversion of the first episode of symptomatic atrial fibrillation: a condition believed to be benign revised.

Becker T, Kleemann T, Strauss M, Doenges K, Schneider S, Senges J, Seidl K.

Clin Res Cardiol. 2008 Feb;97(2):74-82. Epub 2007 Oct 19.

PMID:
17938851
14.
15.

[Therapeutic success of a prospective cardioversion protocol for persistent atrial fibrillation].

Martínez-Brotóns AM, Ruiz-Granell R, Morell S, Plancha E, Ferrero A, Roselló A, Llácer A, García-Civera R.

Rev Esp Cardiol. 2006 Oct;59(10):1038-46. Spanish.

16.

Outcomes after cardioversion and atrial fibrillation ablation in patients treated with rivaroxaban and warfarin in the ROCKET AF trial.

Piccini JP, Stevens SR, Lokhnygina Y, Patel MR, Halperin JL, Singer DE, Hankey GJ, Hacke W, Becker RC, Nessel CC, Mahaffey KW, Fox KA, Califf RM, Breithardt G; ROCKET AF Steering Committee & Investigators.

J Am Coll Cardiol. 2013 May 14;61(19):1998-2006. doi: 10.1016/j.jacc.2013.02.025. Epub 2013 Mar 14.

17.

Predictors of left atrial appendage stunning after electrical cardioversion of non-valvular atrial fibrillation.

Yang S, Huang C, Hu X, Jin L, Li F, Peng S.

Chin Med J (Engl). 2003 Oct;116(10):1445-50.

PMID:
14570597
18.

Safety and efficacy of enoxaparin compared with unfractionated heparin and oral anticoagulants for prevention of thromboembolic complications in cardioversion of nonvalvular atrial fibrillation: the Anticoagulation in Cardioversion using Enoxaparin (ACE) trial.

Stellbrink C, Nixdorff U, Hofmann T, Lehmacher W, Daniel WG, Hanrath P, Geller C, Mügge A, Sehnert W, Schmidt-Lucke C, Schmidt-Lucke JA; ACE (Anticoagulation in Cardioversion using Enoxaparin) Study Group.

Circulation. 2004 Mar 2;109(8):997-1003. Epub 2004 Feb 16.

19.

Brain natriuretic peptide predicts successful cardioversion in patients with atrial fibrillation and maintenance of sinus rhythm.

Beck-da-Silva L, de Bold A, Fraser M, Williams K, Haddad H.

Can J Cardiol. 2004 Oct;20(12):1245-8.

PMID:
15494777
20.

Reduced high serum hepatocyte growth factor levels after successful cardioversion in patients with atrial fibrillation.

Katoh H, Shimada T, Inoue S, Takahashi N, Shimizu H, Ohta Y, Nakamura K, Murakami Y, Ishibashi Y, Matsumori A.

Clin Exp Pharmacol Physiol. 2004 Mar;31(3):145-51.

PMID:
15008956

Supplemental Content

Support Center